Polymyxin B is another clinically available polymyxin that has re-emerged in clinical practice to treat infections caused by multi-drug (MDR) or extensively-drug-resistant (XDR) Gram-negative bacteria (GNB). Its chemical structure is very similar to the structure of polymyxin E (colistin). However, since the latter is administered as a prodrug, there are major pharmacokinetic differences between both polymyxins that may potentially determine different clinical and microbiological outcomes. Studies addressing clinical or microbiological outcomes in patients treated with polymyxin B for MDR or XDR GNB are reviewed in this chapter.
CITATION STYLE
Rigatto, M. H., Falci, D. R., & Zavascki, A. P. (2019). Clinical Use of Polymyxin B. In Advances in Experimental Medicine and Biology (Vol. 1145, pp. 197–218). Springer New York LLC. https://doi.org/10.1007/978-3-030-16373-0_14
Mendeley helps you to discover research relevant for your work.